

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Food-grade nanoparticles for encapsulation, protection and**
2 **delivery of curcumin: Comparison of lipid, protein, and**
3 **phospholipid nanoparticles under simulated gastrointestinal**
4 **conditions**

5
6 **Liqiang Zou^a, Bingjing Zheng^b, Ruojie Zhang^b, Zipei Zhang^b, Wei Liu^{a*},**
7 **Chengmei Liu^a, Hang Xiao^b, David Julian McClements^{b,c*}**

8 ^a *State Key Laboratory of Food Science and Technology, Nanchang University,*
9 *Nanchang, No. 235 Nanjing East Road, Nanchang 330047, Jiangxi, China*

10 ^b *Department of Food Science, University of Massachusetts, Amherst, MA 01003*

11 ^c *Department of Biochemistry, Faculty of Science, King Abdulaziz University, P. O.*
12 *Box 80203 Jeddah 21589, Saudi Arabia*

13
14 *Journal: Advances*

15 *Submitted: November 2015*

16

17 * These authors contributed equally to this manuscript. Contact information:

18 Wei Liu, State Key Laboratory of Food Science and Technology, Nanchang
19 University, Nanchang, 330047, Jiangxi, China Tel: + 86 791 88305872x8106. Fax:
20 +86 791 88334509. E-mail: E-mail: liuwei@ncu.edu.cn.

21

22 David Julian McClements, Department of Food Science, University of Massachusetts,
23 Amherst, MA 01003, USA Tel: (413) 545-1019. Fax: (413) 545-1262. E-mail:
24 mcclements@foodsci.umass.edu.

25

26 **Abstract**

27 The potential of three nanoparticle-based delivery systems to improve curcumin
28 bioavailability was investigated: lipid nPs (nanoemulsions); protein nPs (zein
29 nanosuspensions); and, phospholipid nPs (nanoliposomes). All three nanoparticle
30 types were fabricated from food-grade constituents, had small mean diameters ($d <$
31 200 nm), and had monomodal particle size distributions. The loading capacity of
32 curcumin depended strongly on nanoparticle composition: protein nPs (11.7%);
33 phospholipid nPs (3.1 %); lipid nPs (0.40 %). The curcumin-loaded nanoparticles
34 were passed through a simulated gastrointestinal tract (GIT) consisting of mouth,
35 stomach, and small intestine phases, and curcumin bioaccessibility and degradation
36 were measured. Nanoparticle composition influenced their ability to protect curcumin
37 from chemical degradation (lipid nPs \approx protein nPs $>$ phospholipid nPs) and to
38 increase their solubilization within intestinal fluids (lipid nPs $>$ phospholipid nPs $>$
39 protein nPs). This latter effect was attributed to the enhanced solubilization capacity
40 of the mixed micelle phase formed after digestion of the lipid nanoparticles. Overall,
41 the lipid nanoparticles (nanoemulsions) appeared to be the most effective at
42 increasing the amount of curcumin available for absorption (at an equal initial
43 curcumin level). This study shows that different types of nanoparticles have
44 different advantages and disadvantages for encapsulating, protecting, and releasing
45 curcumin. This research will facilitate the rational selection of food-grade colloidal
46 delivery systems designed to enhance the oral bioavailability of hydrophobic
47 nutraceuticals.

48 **Keywords:** curcumin; zein nanoparticle; nanoemulsion; nanoliposome;
49 bioaccessibility; nutraceutical; delivery system.

50

51 1. Introduction

52 There has been growing interest in the utilization of edible nanoparticles to
53 encapsulate hydrophobic bioactive molecules intended for oral delivery, such as
54 vitamins, nutrients, and nutraceuticals¹⁻³. These nanoparticle-based delivery
55 systems offer certain advantages over other types of delivery systems, including
56 higher optical clarity, greater stability to aggregation and gravitational separation, and
57 enhanced bioavailability^{4,5}. High optical clarity is achieved when the nanoparticles
58 have dimensions appreciably lower than the wavelength of light ($d < \lambda/10$)⁶. Good
59 aggregation stability is due to the fact that the attractive forces between colloidal
60 particles decrease more rapidly than the repulsive interactions with decreasing particle
61 size⁷. Nanoparticles tend to have good stability to creaming or sedimentation
62 because the gravitational forces acting on them are relatively weak, and may be
63 balanced by Brownian motion^{7,8}. An enhancement in bioavailability of
64 encapsulated bioactive components may occur because small particles are hydrolyzed
65 more rapidly than larger ones by digestive enzymes in the gastrointestinal tract (GIT)
66⁹.

67 Edible nanoparticles can be fabricated from various kinds of food components,
68 including surfactants, phospholipids, lipids, proteins, and/or carbohydrates^{2,3,9-12}.
69 The nature of the food components used to assemble a nanoparticle usually dictates
70 the type of fabrication methods that can be used to produce it. In turn, the
71 composition of a nanoparticle determines the physicochemical properties, functional
72 attributes, and gastrointestinal fate of nanoparticle-based delivery systems.
73 Consequently, it is important to be able to identify the most suitable nanoparticle type
74 for a particular application. Ideally, the nanoparticles should be fabricated using
75 simple, reproducible, and inexpensive methods that can easily be scaled up for
76 commercial applications. In addition, it would be advantageous if the nanoparticles
77 could be assembled from label-friendly ingredients, such as natural proteins,
78 phospholipids, and lipids. Moreover, the nanoparticles should have the functional
79 attributes required for the particular application, which will depend on the nature of

80 the bioactive to be encapsulated, as well as on the nature of the food or beverage that
81 the nanoparticles will be utilized in.

82 The objective of this research was to fabricate three different kinds of edible
83 nanoparticle-based delivery system, and then compare their ability to encapsulate,
84 protect, and release an important bioactive agent (curcumin). The term curcumin is
85 typically used to refer to a group of highly hydrophobic molecules found in the spice
86 turmeric, with the three most prevalent forms being curcumin, demethoxycurcumin,
87 and bis-demethoxycurcumin¹³. Curcumin has been shown to exhibit a broad range
88 of potentially beneficial effects on human health and to have low toxicity, which
89 makes it particularly suitable as a nutraceutical or pharmaceutical¹⁴. However, there
90 are a number of practical challenges associated with incorporating curcumin into food
91 products, including its poor water-solubility, its high susceptibility to
92 chemical/biochemical degradation, and its low oral bioavailability¹³. Consequently,
93 there is a need to develop suitable delivery systems to overcome these challenges^{15,16}.
94 In this study, protein nanoparticles were fabricated from a hydrophobic protein (zein)
95 using an antisolvent precipitation method¹⁷. Lipid nanoparticles (nanoemulsions)
96 were fabricated by homogenizing oil and water phases together in the presence of an
97 emulsifier using a microfluidizer¹⁸. Phospholipid nanoparticles (nanoliposomes)
98 were fabricated by homogenizing lecithin and water phases together¹⁹. These three
99 different types of nanoparticles were selected for a number of reasons: they have all
100 previously been shown to be capable of encapsulating hydrophobic nutraceuticals;
101 they are all food grade; they all have potential for commercial application; and, they
102 represent three distinctly different classes of nanoparticles.

103 A major aim of this study was to elucidate the physicochemical phenomena
104 underlying the ability of these different types of nanoparticles to encapsulate, protect,
105 and release curcumin. This information could then be used to establish their relative
106 advantages and disadvantages as colloidal delivery systems for particular applications.
107 Each of the curcumin-enriched nanoparticle suspensions was passed through a
108 simulated GIT, and changes in the physicochemical and structural properties of the
109 delivery systems were measured. In addition, the influence of nanoparticle carrier

110 material on the chemical transformation and bioaccessibility of the curcumin was
111 determined. The results of this research should therefore provide useful information
112 that can be used to select the most appropriate food-grade colloidal delivery system
113 for a particular application.

114 **2. Materials and methods**

115 **2.1. Materials**

116 Corn oil purchased from a local supermarket was used as an example of a
117 digestible long chain triglyceride (LCT). The phospholipid (90G) was provided by
118 Lipoid GmbH (Ludwigshafen, Germany), which was reported to contain 96.6%
119 phosphatidylcholine by the manufacturer. The hydrophobic protein zein (Lot
120 SLBD5665V) was purchased from Sigma–Aldrich (St. Louis, MO, USA). The
121 following chemicals were also purchased from the Sigma Chemical Company:
122 curcumin (SLBH2403V), mucin from porcine stomach (SLBH9969V), pepsin from
123 porcine gastric mucosa (SLBL1993V), lipase from porcine pancreas pancreatin
124 (SLBH6427V), porcine bile extract (SLBK9078), Tween 80 (BCBG4438V), and Nile
125 Red (063K3730V). All other chemicals were of analytical grade. Double distilled
126 water was used to prepare all solutions and nanoparticle suspensions.

127 **2.2. Fabrication of edible nanoparticles**

128 *2.2.1. Lipid nanoparticles*

129 Curcumin-loaded lipid nanoparticles were formed by homogenizing aqueous and
130 oil phases together using a microfluidizer¹⁸. An aqueous phase was prepared by
131 mixing 1% (w/w) Tween 80 (a food-grade non-ionic surfactant) with an aqueous
132 buffer solution (5.0 mM phosphate buffer saline (PBS), pH 6.5) and stirring for at
133 least 2 h. The oil phase consisted of varying amounts of curcumin dissolved in corn
134 oil. Then, 10% (w/w) oil phase and 90% (w/w) aqueous phase were blended together
135 using a high-shear mixer for 2 min (M133/1281-0, Biospec Products, Inc., ESGC,
136 Switzerland) to form a coarse emulsion. Nanoemulsions were then prepared by

137 passing the coarse emulsion three times through a microfluidizer (M110Y,
138 Microfluidics, Newton, MA) with a 75 μm interaction chamber (F20Y) at an
139 operational pressure of 12,000 psi.

140 *2.2.2. Protein nanoparticles*

141 Curcumin-loaded protein nanoparticles were fabricated from zein using an
142 antisolvent precipitation method¹⁷. Initially, curcumin and zein (26.4 mg/mL) were
143 dissolved in ethanol solution (80% V/V) at different mass ratios. Then, 25 mL of
144 aqueous ethanol solution was rapidly injected into 75 ml of Tween 80 solution (PBS,
145 pH=4.0) that was continuously stirred at 1200 rpm using a magnetic stirrer (IKA R05,
146 Werke, GmbH). The resulting colloidal dispersion was then stirred for another 30 min
147 at the same speed. The ethanol remaining in the final colloidal dispersions was
148 evaporated using a rotary evaporator (Rotavapor R110, Büchi Crop., Switzerland),
149 and the same volume of pH 4.0 PBS was added to compensate for the lost ethanol.

150 *2.2.3. Phospholipid nanoparticles*

151 Curcumin-loaded phospholipid nanoparticles were formed using an ethanol
152 injection-microfluidizer method described previously¹⁹. Phospholipid (14 mg/mL)
153 and curcumin were mixed in different mass ratios. The mixture was then dissolved in
154 50 mL anhydrous ethanol and quickly injected into the same volume of PBS solution
155 (pH 6.5, 0.05 M). The resulting mixture was stirred vigorously for half an hour,
156 resulting in the formation of a milky dispersion due to liposome formation. This
157 dispersion was then transferred to a rotary evaporator maintained at 45 °C using a
158 water bath, and then the ethanol was removed under reduced pressure. The
159 curcumin-loaded liposomes obtained by the ethanol injection method were then
160 passed through a microfluidizer (M110Y, Microfluidics, Newton, MA) with a 75 μm
161 interaction chamber (F20Y) at an operational pressure of 12,000 psi.

162 *2.2.4. Nanoparticle compositions*

163 For the determination of the curcumin loading capacity a series of nanoparticles
164 was prepared with different curcumin levels. For the remainder of the experiments,

165 the nanoparticle-based delivery systems were prepared so that they all contained the
166 same initial curcumin concentration (0.3 mg/mL). Due to the fact that the loading
167 capacities of the different nanoparticles varied, this meant that the delivery systems
168 had to be formulated to contain different amounts of carrier material inside the
169 particles. Hence, the final levels of carrier materials in the three different delivery
170 systems were 6.6 mg/mL for protein, 100 mg/mL for lipid, and 14 mg/mL for
171 phospholipid.

172 **2.3. Determination of curcumin loading capacity**

173 The maximum amount of curcumin that could be loaded into the different
174 nanoparticle systems was characterized by measuring the loading capacity:

175

$$176 \quad LC = 100 \times m_C/m_T \quad (1)$$

177

178 Here, m_C is the maximum mass of curcumin than can be loaded into the nanoparticles,
179 and m_T is the total mass of the nanoparticles (curcumin + wall material). The
180 loading capacity was determined by preparing a series of delivery systems containing
181 increasing amounts of curcumin: 0.3, 0.35, 0.4, 0.45 mg/mL for lipid nPs; 0.5, 0.75,
182 and 1 mg/mL for phospholipid nPs; 0.5, 0.75, 1, 1.25 mg/mL for protein nPs. The
183 concentration of curcumin encapsulated in a delivery system was then measured used
184 a UV-visible spectrophotometer method based on one described previously¹⁸. 10 mL
185 of sample was collected, and then centrifuged at 4000 rpm for 30 min at ambient
186 temperature (CL10 centrifuge, Thermo, Scientific, Pittsburgh, PA, USA) to remove
187 any non-encapsulated curcumin. 1 mL of the resultant supernatant was then mixed
188 with 5 mL of chloroform, vortexed, and then centrifuged at 1750 rpm ($\approx 940 \times g$) for
189 10 min at ambient temperature. The bottom layer containing the solubilized curcumin
190 was collected, while the top layer was mixed with an additional 5 mL of chloroform
191 and the same procedure was repeated. The two bottom chloroform layers were
192 combined, and diluted to an appropriate concentration to be analyzed by a UV-visible
193 spectrophotometer at a wavelength of 419 nm (Ultraspec 3000 pro, GE Health

194 Sciences, USA). The concentration of curcumin extracted from each
195 nanoparticle-dispersion was calculated from a calibration curve of absorbance *versus*
196 curcumin concentration in chloroform.

197 **2.4. Color analysis of nanoparticle suspensions**

198 The influence of the nanoparticles on the optical properties of the delivery
199 systems was determined by measuring their color. The three different types of
200 nanoparticle delivery systems were prepared so that the final curcumin concentration
201 in each of them was similar (0.3 mg/mL). The color coordinates of the
202 curcumin-loaded delivery systems were then characterized using an instrumental
203 colorimeter (ColorFlex EZ 45/0-LAV, Hunter Associates Laboratory Inc., Virginia,
204 USA). Color was expressed in CIE units as L^* (lightness/darkness), a^*
205 (redness/greenness), and b^* (yellowness/blueness). An aliquot of sample (15 mL) was
206 placed in a 64-mm path length glass sample cup and then illuminated with
207 D65-artificial daylight (10° standard angle). Three replicate measurements were
208 performed and the results were averaged.

209 **2.5. Particle characterization**

210 The particle size distribution of the curcumin-loaded delivery systems was
211 determined using both static light scattering (SLS) and dynamic light scattering (DLS)
212 to cover the wide particle range that occurred.

213 For the SLS measurements, samples were diluted with appropriate buffer
214 solutions (same pH as sample) and then stirred in the dispersion cell of the instrument
215 at a speed of 1200 rpm to ensure homogeneity. Information about the particle size was
216 then obtained by analyzing the light scattering pattern (Mastersizer 2000, Malvern
217 Instruments Ltd., Worcestershire, UK). The data is reported as the full particle size
218 distribution or as the surface-weighted (d_{32}) and volume-weighted (d_{43}) mean
219 diameter calculated from this distribution. The electrical charge (ζ -potential) of the
220 particles in the samples was measured using a micro-electrophoresis instrument
221 (Nano-ZS, Malvern Instruments, Worcestershire, UK). Samples were diluted with

222 appropriate buffer solutions (same pH as sample) prior to measurements to avoid
223 multiple scattering effects.

224 The mean particle diameter (Z-average) and electrical charge (ζ -potential) of the
225 particles in the mixed micelle phase collected by centrifugation of the digesta was
226 determined by a combined dynamic light scattering / micro-electrophoresis instrument
227 (Nano-ZS, Malvern Instruments, Worcestershire, UK). The mixed micelle phase was
228 diluted with buffer solution (5 mM PBS, pH 7.0) prior to measurements to avoid
229 multiple scattering effects.

230 **2.6. Microstructural analysis**

231 The microstructure of the various samples was characterized using confocal
232 scanning fluorescence microscopy (Nikon D-Eclipse C1 80i, Nikon, Melville, NY).
233 Prior to analysis the samples were dyed with Nile Red (0.1%) to highlight the location
234 of the non-polar lipid regions. All images were captured with a 10 \times eyepiece and a
235 60 \times objective lens (oil immersion).

236 **2.7. Simulated gastrointestinal digestion**

237 The potential gastrointestinal fate of the three different types of
238 nanoparticle-based delivery systems was analyzed by passing them through an *in vitro*
239 GIT model that consisted of mouth, stomach, and small intestine phases, which was
240 slightly modified from our previous study²⁰. All solutions and samples were
241 incubated at 37 °C prior to use, and maintained at this temperature throughout the GIT
242 model.

243 *Initial system:* The initial samples (which all contained the same curcumin
244 concentration) were placed into a glass beaker in a temperature-controlled shaker
245 (Innova Incubator Shaker, Model 4080, New Brunswick Scientific, New Jersey,
246 USA).

247 *Mouth phase:* A simulated saliva fluid (SSF) containing 3 mg/mL mucin and
248 various salts was prepared, and then mixed with the sample being tested at a 1:1 mass

249 ratio. The resulting mixtures were then adjusted to pH 6.8 and placed in a shaking
250 incubator at 90 rpm for 10 min to mimic oral conditions

251 *Stomach phase:* Simulated gastric fluid (SGF) was prepared by placing 2 g NaCl
252 and 7 mL HCl into a container, and then adding double distilled water to 1 L. The
253 bolus sample from the mouth phase was then mixed with SGF containing 0.0032
254 g/mL pepsin preheated to 37 °C at a 1:1 mass ratio. The mixture was then adjusted to
255 pH 2.5 and placed in a shaker at 100 rpm for 2 hours to mimic stomach digestion.

256 *Small Intestine phase:* 30 mL chyme samples from the stomach phase were
257 diluted with 30 mL buffer solution (10 mM PBS, 6.5). The diluted chyme was then
258 incubated in a water bath for 10 min and then the solution was adjusted back to pH
259 7.0. Next, 3 mL of simulated intestinal fluid (containing 0.5 M CaCl₂ and 7.5 M NaCl)
260 was added to 60 mL digesta. Then, 7 mL bile extract, containing 375.0 mg bile extract
261 (pH 7.0, PBS), was added with stirring and the pH was adjusted to 7.0. Finally, 5 mL
262 of lipase suspension, containing 120 mg of lipase (pH 7.0, PBS), was added to the
263 sample and an automatic titration unit (Metrohm, USA Inc.) was used to monitor the
264 pH and control it to a fixed value (pH 7.0) by titrating 0.05 M NaOH (for protein and
265 phospholipid nanoparticles) or 0.25 M NaOH (for lipid nanoparticles) solutions into
266 the reaction vessel for 2 h.

267 The static GIT model used in this study cannot accurately mimic the complex
268 physicochemical events and physiological environments experienced by foods within
269 the human gastrointestinal tract. Nevertheless, this type of method is useful for
270 identifying key physicochemical phenomena that may occur within the GIT, as well
271 as for rapidly screening samples with different compositions or structures. Once
272 suitable candidates have been identified, then they should be further tested using
273 animal or human feeding studies.

274 **2.8. Curcumin concentration and bioaccessibility after digestion**

275 After *in vitro* digestion, 20 mL raw digesta of each mixture was centrifuged
276 (18000 rpm, $\approx 38,465 \times g$, Thermo Scientific, Waltham, MA, USA) at 25 °C for 30
277 min. The clear supernatant was collected and assumed to be the “micelle” fraction in

278 which the curcumin was solubilized. In some samples, a layer of non-digested oil was
279 observed at the top of the test tubes and it was excluded from the micelle fraction.
280 Aliquots of 5 mL of raw digesta or micelle fraction were mixed with 5 mL of
281 chloroform, vortexed and centrifuged at 1750 rpm ($\approx 940 \times g$) for 10 min at ambient
282 temperature. The bottom layer containing the solubilized curcumin was collected,
283 while the top layer was mixed with an additional 5 mL of chloroform and the same
284 procedure was repeated. The two collected chloroform layers were mixed together,
285 and then diluted to an appropriate concentration to be analyzed by a UV-visible
286 spectrophotometer at 419 nm. The curcumin concentrations in the overall digesta and
287 in the mixed micelle phase were calculated from the absorbance using a standard
288 curve.

289 The transformation and bioaccessibility of the curcumin were then calculated
290 from this data using the following equations:

$$291 \quad \text{Transformation} = 100 \times (C_{\text{Digesta}} / C_{\text{Initial}}) \quad (2)$$

$$292 \quad \text{Bioaccessibility} = 100 \times (C_{\text{Micelle}} / C_{\text{Digesta}}) \quad (3)$$

293 Here, C_{Micelle} and C_{Digesta} are the concentrations of curcumin in the mixed micelle
294 fraction and in the overall digesta after the pH-stat experiment, respectively. The
295 transformation provides an indication of the amount of curcumin that is not
296 chemically/biochemically degraded during passage throughout the GIT, whereas the
297 bioaccessibility gives an indication of the fraction of curcumin reaching the small
298 intestine that is solubilized within the micelle phase and therefore available for
299 absorption.

300 It should be noted that the centrifugation method used in this study is intended to
301 separate mixed micelles (and any solubilized bioactive components) from other
302 particulate matter in the digesta. In principle, sufficiently small and stable
303 nanoparticles may not be separated from the mixed micelle phase by centrifugation.
304 However, this should not be a problem in this work because the lipid and protein
305 nanoparticles should be fully digested, while the phospholipid nanoparticles should be
306 disassembled and incorporated into the mixed micelle phase.

307 **2.9. Statistical analysis**

308 All experiments were carried out on two or three freshly prepared samples. The
309 results are expressed as means \pm standard deviations (SD). Data were subjected to
310 statistical analysis using SPSS software (version 18.0). Means were subject to
311 Duncan's test and a P -value of <0.05 was considered statistically significant.

312 **3. Results and discussion**

313 **3.1. Properties of initial nanoparticle delivery systems**

314 Initially, we compared the characteristics of the three different types of
315 nanoparticle-based delivery systems after they have been prepared. The three
316 fabrication methods used all led to the production of stable colloidal dispersions that
317 contained relatively small particles. Dynamic light scattering measurements
318 indicated that all three colloidal dispersions had relatively narrow monomodal particle
319 size distributions ($PDI < 0.35$) and contained relatively small particles: $d = 192, 153,$
320 and 89 nm for lipid-, protein-, and phospholipid-nPs, respectively (**Table 1, Figure**
321 **1a**). However, there was a discrepancy between the mean particle sizes determined
322 by static and dynamic light scattering instruments. DLS measurements indicated
323 that the phospholipid-nPs were appreciably smaller than the protein- or lipid-nPs,
324 whereas SLS measurements suggested that the phospholipid- and protein-nPs had
325 similar dimensions (**Table 1**). This discrepancy probably occurred because the SLS
326 instrument is not sensitive to small particles ($d < 100$ nm), and may therefore not have
327 provided accurate measurements for the phospholipid-nPs. This observation
328 highlights the importance of using an appropriate particle sizing technology to
329 analyze the particles in colloidal dispersions. It should be noted that for each type of
330 nanoparticle used it is possible to produce different particle size distributions by
331 altering the preparation conditions.

332 Visual observation of the colloidal dispersions indicated that they had distinctly
333 different appearances (**Figure 1b**). The dispersion containing phospholipid-nPs
334 appeared to be relatively clear, the one containing protein-nPs was only slightly turbid,

335 and the one containing lipid-nPs was cloudy. The visual observations were
336 supported by instrumental colorimetry measurements, which indicated that the
337 lightness (L) and yellow color (b^+) of the different systems followed the order: lipid
338 nPs > protein nPs > phospholipid nPs. These differences in optical properties can be
339 attributed to differences in the light scattering patterns of the different colloidal
340 dispersions, which depend on particle concentration, size, and refractive index^{6,21}.
341 Even though the concentration of curcumin was the same in each of the systems, the
342 concentration of nanoparticles was different because of their different loading
343 capacities (see later). The concentration of nPs in the system decreased in the
344 following order: lipid (100 mg/mL) >> phospholipid (14 mg/mL) > protein (6.6
345 mg/mL). The relatively high opacity of the suspension of lipid nanoparticles may
346 therefore be attributed to the fact that it had a high particle concentration, and so there
347 was greater light scattering. On the other hand, the high optical clarity of the
348 suspension of phospholipid nPs is probably because it contained particles that were
349 much smaller than those in the other two systems. For certain applications it is
350 important that functional food products are optically transparent, such as many soft
351 drinks and fortified waters. In these cases, it may be more advantageous to use
352 phospholipid nanoparticles than other types.

353 Confocal microscopy images indicated that the nanoparticles in the three
354 colloidal dispersions were evenly distributed throughout the samples, *i.e.*, there was
355 no evidence of extensive particle aggregation (**Figure 1c**). Previous electron
356 microscopy characterization of nanoparticles produced using similar fabrication
357 methods as the ones used in this study have shown that the lipid-based²²,
358 protein-based²³, and phospholipid-based²⁴ nanoparticles.

359 Measurements of the electrical characteristics of the nanoparticles indicated that
360 they varied considerably depending on their compositions (**Table 1**). The protein-nPs
361 initially had a strong positive charge (+20.4 mV) because the pH of the solution (pH 4)
362 used during their preparation was well below the isoelectric point of the zein (pI \approx 6.2)
363²⁵. The phospholipid- and lipid-nPs both had fairly low negative charges (-5 to -7
364 mV, pH 6.5). The low charge on the lipid nanoparticles is to be expected because

365 they were coated by a non-ionic surfactant. The low charge on the phospholipids
366 may have been due to the nature of their head groups. It is known that there are
367 appreciable differences between the electrical characteristics of phospholipids from
368 different sources depending on head group type ²⁶.

369 The loading capacity of the different types of nanoparticles was also determined
370 (**Table 1**). An appreciably higher amount of curcumin could be successfully
371 incorporated into the protein-nPs (11.7%), than the phospholipid-nPs (3.1%), or the
372 lipid-nPs (0.4%). Curcumin is a relatively hydrophobic molecule, but it does have
373 some polar groups also, including multiple alcohol and carbonyl groups ¹³.
374 Consequently, it may dissolve better in an environment that contains a mixture of
375 polar and non-polar regions (proteins and phospholipids), rather than only non-polar
376 regions (lipids). This result means that to reach the same curcumin level in a
377 functional food product a much higher amount of lipid or phospholipid would be
378 required to fabricate nanoparticle delivery systems than protein. The utilization of
379 higher nanoparticle concentrations may impact the cost, physicochemical properties,
380 and sensory attributes of a food product (such as appearance, texture, or mouthfeel).
381 This factor should therefore be taken into account when developing a suitable
382 nanoparticle-based delivery system for a particular application.

383 **3.2. Gastrointestinal fate of different nanoparticles**

384 After preparation, the nanoparticle-based delivery systems were passed through a
385 simulated GIT that included mouth, stomach, and small intestine phases. This
386 relatively simple static GIT model was based on recent attempts to standardize
387 methods so that results could be compared between different research groups ^{27, 28}.
388 Changes in particle size, structural organization, and charge were recorded to provide
389 some insight into the behavior of the different types of nanoparticles under GIT
390 conditions (**Figures 2 to 5**).

391 *Mouth:* After exposure to simulated oral conditions there was a large increase in
392 the mean particle size of the systems containing protein- and phospholipid-nPs, but
393 little change in the systems containing lipid-nPs (**Figure 2**). The particle size

394 distribution measurements indicated that this was due to the presence of a population
395 of particles with dimensions much larger than those in the initial systems (**Figure 3**).
396 As expected, large aggregates were also observed in the confocal microscopy images
397 for the colloidal dispersions containing protein- and phospholipid-nPs in the mouth
398 stage (**Figure 4**). For these nanoparticles, aggregation may have been partially due
399 to depletion flocculation induced by the mucin molecules, as well as partially due to
400 electrostatic screening effects caused by the salts in the artificial saliva. In addition,
401 anionic groups on the mucin molecules may have bound to cationic groups on the
402 phospholipid head groups (such as the amino groups found on phosphatidylcholine
403 and phosphatidylethanolamine) or cationic groups on the protein molecule surfaces
404 (such as the amino groups found on arginine, lysine or histidine). Interestingly, the
405 confocal microscopy images indicated that extensive aggregation of the lipid-nPs
406 occurred within the oral phase (**Figure 4**), despite the fact that aggregation was not
407 evident in the light scattering data (**Figures 2 and 3c**). This effect has also been
408 reported previously, where it was attributed to the ability of mucin to promote
409 reversible depletion flocculation. In the simulated mouth conditions, the mucin
410 concentration is above the critical level required to induce flocculation, but once the
411 samples are diluted for light scattering measurements the mucin concentration is no
412 longer high enough. This result highlights the importance of confirming light
413 scattering measurements with microscopy observations; otherwise erroneous
414 conclusions may be drawn. Presumably, the phospholipid- and protein-nPs remained
415 aggregated after dilution because strong electrostatic mucin bridges held them
416 together.

417 In the mouth stage, all of the colloidal dispersions had a relatively modest
418 negative charge (-7 to -9 mV). This would be expected for the lipid- and
419 phospholipid-nPs because the mouth pH was close to their initial values. The
420 negative charge on the protein-nPs may have been because the pH in the mouth (pH 7)
421 was higher than the isoelectric point of zein (pH 6.2). In addition, some anionic
422 mucin molecules may have adsorbed to the cationic groups on the surfaces of the
423 protein or phospholipid molecules.

424 *Stomach:* After exposure to stomach conditions the mean particle diameters of the
425 protein- and phospholipid-nPs determined by light scattering remained relatively large
426 (**Figure 2**), which suggested that they were strongly aggregated. On the other hand,
427 the mean particle diameter of the lipid-nPs was similar to that of the initial sample.
428 These results were supported by the full particle size distributions, which showed that
429 there was a population of large particles in the systems containing protein- and
430 phospholipid-nPs (**Figure 3**). Interestingly, there appeared to be a population of
431 nanoparticles with dimensions similar to the initial ones in the colloidal dispersions
432 containing phospholipid-nPs after exposure to the stomach, which suggested that
433 some of the flocs formed in the mouth had dissociated. The confocal microscopy
434 images indicated that there were some large particles in the protein- and
435 phospholipid-nP systems in the stomach, but these particles were smaller than those
436 observed in the mouth (**Figure 4**). In addition, the lipid-nP systems appeared to be
437 non-aggregated in the stomach phase. Thus, the microscopy measurements suggest
438 that some of the flocs formed in the mouth dissociated when they reached the stomach
439 environment. This effect can be attributed to the fact that the samples were diluted
440 in the stomach, which decreased the mucin concentration and therefore reduced the
441 strength of the depletion attraction between the particles. In addition, the pH
442 changed from neutral to strongly acidic, which may have altered the sign, strength,
443 and range of the colloidal interactions between the nanoparticles.

444 All three types of nanoparticles had a small negative charge after exposure to the
445 stomach environment (-3 to -4 mV). It would be expected that zein nanoparticles
446 would have a large positive charge when suspended in highly acidic solutions because
447 the pH would be well below their isoelectric point²⁵. The fact that they actually had
448 a slightly negative charge can be attributed to a number of factors: (i) adsorption of
449 anionic mucin molecules onto the surfaces of the cationic protein nanoparticles; (ii)
450 electrostatic screening by the counter-ions in the simulated gastric fluids; (iii)
451 digestion of the protein molecules by proteases in the gastric fluids. Knowledge of
452 the actual charge on nanoparticles under complex gastrointestinal conditions is
453 important because it may influence the fate of encapsulated bioactives. For example,

454 it is often claimed that cationic nanoparticles have a greater retention in the GIT
455 because they bind to the anionic mucus layer lining the gastrointestinal wall, i.e., they
456 exhibit mucoadhesion²⁹. However, if a layer of anionic mucin from the saliva coats
457 the cationic nanoparticles, this assumption may no longer be valid.

458 *Small intestine:* After exposure to small intestine conditions, light scattering
459 measurements indicated that all of the samples had relatively high mean particle
460 diameters (**Figures 2**) and contained a population of large particles (**Figure 3**). In
461 addition, the confocal microscopy images also indicated that the samples contained
462 some relatively large particles (**Figure 4**). It is difficult to accurately determine the
463 nature of these particles because the digesta may contain undigested nanoparticles,
464 micelles, vesicles, calcium salts, and precipitated curcumin. The electrical charge on
465 the particles in the digesta was highly negative for all of the samples, but the
466 magnitude of the charge was much greater for the lipid-nPs (-47 mV) than for the
467 phospholipid (-26 mV) or protein (-20 mV) ones (**Figure 5**). The negative charge on
468 the particles in the digesta can be attributed to the presence of various types of anionic
469 species, including bile salts, phospholipids, free fatty acids, and peptides. The much
470 greater negative charge measured for the digesta arising from the lipid nPs can be
471 attributed to the fact that long chain free fatty acids were generated that accumulated
472 at the particle surfaces³⁰.

473 **3.3. Digestion of different nanoparticles under intestinal conditions**

474 The small intestine contains a number of different kinds of enzymes that are
475 capable of digesting food components, including amylases, lipases, phospholipases,
476 and proteases³¹. In this section, we therefore characterized the hydrolysis of the
477 different delivery systems under simulated small intestine conditions. An automatic
478 titration unit (pH stat) was used to measure the amount of alkaline solution (NaOH)
479 that had to be added into the reaction chamber to maintain the pH at neutral during the
480 course of digestion²⁷. Lipids and phospholipids will release free fatty acids (and H⁺)
481 when they are hydrolyzed by lipases or phospholipases, whereas proteins will release
482 amino acids (and H⁺) when they are hydrolyzed by proteases.

483 There was a rapid increase in the amount of NaOH titrated into the reaction
484 chamber for the lipid-nP system during the first 10 minutes of digestion, followed by
485 a more modest increase at longer incubation times (**Figure 6**). This release profile can
486 be attributed to the hydrolysis of the triacylglycerols (TAGs) in the lipid nanoparticles
487 leading to the generation of free fatty acids (FFAs) and monoacylglycerols (MAGs).
488 Typically, hydrolysis occurs rapidly in nanoemulsions because of the high surface
489 area of the lipid phase exposed to the digestive enzymes²⁸. In the case, of the
490 protein- and phospholipid-nPs there was only a slight increase in the amount of NaOH
491 added over time. One of the main reasons for this effect is that the three colloidal
492 delivery systems were formulated to contain the same initial curcumin concentration
493 (0.3 mg/mL). As the loading capacities of the different nanoparticles varied (Section
494 3.1), this meant that they had to be formulated with different total amounts of particle
495 carrier material (protein, lipid, or phospholipid). Indeed, the final amounts of
496 proteins, lipids, and phospholipids in the different delivery systems were 6.6 mg/mL
497 for protein, 100 mg/mL for lipid, and 14 mg/mL for phospholipid. Consequently,
498 one would have expected a much greater amount of NaOH would be required to
499 neutralize the protons released for the lipid than for the other carrier materials.

500 In the case of the phospholipid-nPs this may also have been because
501 phospholipases were not specifically included in the simulated small intestinal fluids.
502 Nevertheless, the manufacturer of the pancreatin from porcine pancreas used in this
503 study (Sigma) reports that it has broad-spectrum activity because it contains a mixture
504 of different digestive enzymes. In the case of the protein-nPs this may have been
505 because they had already been largely digested by pepsin within the gastric
506 environment.

507 **3.4. Impact of nanoparticle type on transformation and bioaccessibility**

508 Finally, the influence of the composition of the nanoparticles on the
509 transformation and bioaccessibility of the curcumin at the end of the simulated GIT
510 was determined (**Table 2**). The transformation of a bioactive agent determines the
511 amount that remains in a bioactive form, whereas the bioaccessibility determines the

512 fraction of the bioactive form that is solubilized in the mixed micelle phase and
513 therefore available for absorption. The transformation and bioaccessibility
514 determine the total amount of curcumin available for absorption (**Figure 7**).

515 The fraction of curcumin that was not transformed after passage through the GIT
516 was appreciably higher for the protein-nPs (41%) and lipid-nPs (40%) than for the
517 phospholipid-nPs (21%) (**Table 2**). There are a number of physicochemical factors
518 that could contribute to the chemical stability of the curcumin in the simulated GIT.
519 Firstly, the degradation of curcumin occurs primarily due to exposure to aqueous
520 neutral or alkaline environments^{13,14}. Consequently, if a nanoparticle can prevent
521 the curcumin from coming into contact with the surrounding aqueous phase
522 (especially in the mouth and small intestine stages due to their relatively high pH
523 values), then it may be able to inhibit curcumin degradation. It is possible that the
524 curcumin molecules encapsulated within nanoliposomes are in closer contact with the
525 aqueous phase than those in protein- or lipid-nPs. The phospholipid nanoparticles
526 were appreciably smaller than the other types of nanoparticles, and would therefore
527 have a greater surface area exposed to the aqueous phase. In addition, there may
528 have been water molecules located between the phospholipid bilayers, so that the
529 curcumin was always in close proximity to the aqueous phase. Conversely, the
530 curcumin in the protein- and lipid-nPs may have been present mainly in the interior of
531 the nanoparticles, away from the aqueous phase. Secondly, the degradation of
532 curcumin may be retarded by the presence of certain types of chemical inhibitors,
533 such as antioxidants (that slow down oxidation reactions), chelating agents (that bind
534 molecules that promote degradation), and buffering agents (that control the local pH).
535 Many proteins are known to be effective antioxidants, chelating agents, and buffering
536 agents^{32,33}, which may at least partially account for the relatively good stability of the
537 curcumin in the protein-nPs.

538 The bioaccessibility of the curcumin was appreciably higher in the lipid-nPs
539 (92%) than in the phospholipid-nPs (74%) or protein-nPs (52%). This effect can be
540 attributed to the impact of the digested nanoparticles on the solubilization capacity of
541 the mixed micelle phase. The TAGs from the lipid nanoparticles will be converted

542 into MAGs and FFAs that will form mixed micelles (micelles and vesicles) with the
543 phospholipids and bile salts from the simulated intestinal fluids³⁴. The greater
544 number of non-polar domains formed within the mixed micelle phase due to the
545 presence of the MAGs and FFAs will increase its solubilization capacity. Thus,
546 more hydrophobic curcumin molecules can be solubilized. Phospholipids and their
547 digestion products (lysolecithin and FFAs) released from nanoliposomes could also
548 increase the solubilization capacity of the mixed micelle phase by increasing the
549 number of non-polar domains available to incorporate hydrophobic bioactives³⁵.
550 Conversely, the proteins and peptides released from the zein nanoparticles may not
551 have been able to greatly increase the solubilization capacity of the mixed micelle
552 phase because they cannot easily be incorporated into micelles or vesicles.
553 Nevertheless, studies have shown that the water-solubility of curcumin can be
554 enhanced somewhat by binding to certain types of protein, *e.g.*, soy proteins³⁶, whey
555 proteins³⁷, and caseins³⁸. Curcumin normally has a low solubility in intestinal
556 fluids and therefore the modestly high value (52%) determined for the protein-nPs in
557 this study may have been due to this effect.

558 The absolute amount of curcumin present in the mixed micelle phase after
559 passage through the simulated GIT can be taken as a measure of that which is
560 available for absorption. Overall, the amount of available curcumin depended
561 strongly on nanoparticle composition (**Figure 7**): lipid-nPs > protein-nPs >
562 phospholipid-nPs. This effect can be attributed to the combined influence of the
563 nanoparticle type on both bioaccessibility and transformation. Ideally, a good
564 delivery system should protect the curcumin from degradation throughout the GIT,
565 but then fully release it into the mixed micelle phase in the small intestine. Our results
566 suggest that the lipid nanoparticles were the most effective at promoting both the
567 chemical stability and solubilization of curcumin under GIT conditions.
568 Nevertheless, it should be highlighted that the lipid-nPs actually had the lowest
569 loading capacity (Table 1), and therefore a higher amount of these particles would
570 have to be incorporated into a food to reach a particular curcumin level.

571 In this study, a relatively simple UV-visible spectrophotometry method was used

572 to determine the amount of curcumin present. In future studies, it would be
573 advantageous to use more sophisticated analytical methods, such as HPLC/mass
574 spectrometry, to provide more detailed information about changes in the chemical
575 structure of curcumin throughout the GIT.

576 **4. Conclusions**

577 This study has shown that the composition of the nanoparticles used to
578 encapsulate curcumin has a major impact on its degradation and bioaccessibility
579 within a simulated gastrointestinal tract. Protein nanoparticles were able to
580 incorporate the highest amount of curcumin per unit mass of particles, and so they
581 could be used at the lowest level to fortify foods. This may be advantageous in
582 terms of lower costs, and reduced impact on the quality attributes of foods (such as
583 appearance, texture, and flavor). Nevertheless, future studies need to be carried out
584 to determine the influence of different nanoparticle types on sensory properties using
585 commercially realistic products. At a fixed curcumin level, the lipid nanoparticles
586 (nanoemulsions) were the most effective at increasing the amount of bioactive
587 available for absorption, which was attributed to their ability to protect the curcumin
588 from degradation and increase its solubility in the mixed micelle phase. The greatest
589 amount of chemical degradation of curcumin occurred when it was incorporated into
590 phospholipid-nanoparticles (nanoliposomes), which may limit the application of this
591 type of delivery system. The main advantage of protein nanoparticles was that they
592 had a high loading capacity, which meant that they could be used at relatively low
593 levels to fortify foods or other products with curcumin.

594 The results of this study highlight the importance of selecting an appropriate type
595 of nanoparticle-based delivery system to optimize the bioavailability of curcumin.
596 There are advantages and disadvantages for each kind of nanoparticle, which should
597 be taken into account for different types of applications. A relatively simple *in vitro*
598 gastrointestinal model was used in this study, which enabled us to rapidly screen
599 different samples and to provide some insights into the physicochemical mechanisms
600 occurring. Nevertheless, further work is clearly required using animal or human

601 feeding models to determine if the effects observed will also occur under more
602 realistic gastrointestinal conditions.

603 **5. Acknowledgements**

604 This material was partly based upon work supported by the USDA, NRI Grants
605 (2013-03795, 2011-67021, and 2014-67021). We also thank the National Aero and
606 Space Administration (NASA) for partial funding of this research (NNX14AP32G).
607 This project was also partly supported by the National Natural Science Foundation of
608 China (NSFC31428017). This project was also partly funded by the Deanship of
609 Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant numbers
610 330-130-1435-DSR, 299-130-1435-DSR, 87-130-35-HiCi. The authors, therefore,
611 acknowledge with thanks DSR technical and financial support.
612

6. References

1. D. J. McClements, *Journal of Food Science*, 2015, **80**, N1602-N1611.
2. J. S. Yang, S. Y. Han, H. C. Zheng, H. B. Dong and J. B. Liu, *Carbohydrate Polymers*, 2015, **123**, 53-66.
3. H. Y. Kim, S. S. Park and S. T. Lim, *Colloids and Surfaces B-Biointerfaces*, 2015, **126**, 607-620.
4. D. J. McClements and J. Rao, *Critical Reviews in Food Science and Nutrition*, 2011, **51**, 285-330.
5. L. Sagalowicz and M. E. Leser, *Current Opinion in Colloid & Interface Science*, 2010, **15**, 61-72.
6. D. J. McClements, *Advances in Colloid and Interface Science*, 2002, **97**, 63-89.
7. D. J. McClements, *Soft Matter*, 2011, **7**, 2297-2316.
8. T. G. Mason, J. N. Wilking, K. Meleson, C. B. Chang and S. M. Graves, *Journal of Physics-Condensed Matter*, 2006, **18**, R635-R666.
9. D. J. McClements, *Progress in Lipid Research*, 2013, **52**, 409-423.
10. M. Fathi, A. Martin and D. J. McClements, *Trends in Food Science & Technology*, 2014, **39**, 18-39.
11. Z. L. Wan, J. Guo and X. Q. Yang, *Food & Function*, 2015, **6**, 2876-2889.
12. M. R. Mozafari, C. Johnson, S. Hatziantoniou and C. Demetzos, *Journal of Liposome Research*, 2008, **18**, 309-327.
13. M. Heger, R. F. van Golen, M. Broekgaarden and M. C. Michel, *Pharmacological reviews*, 2014, **66**, 222-307.
14. P. Anand, A. B. Kunnumakkara, R. A. Newman and B. B. Aggarwal, *Molecular Pharmaceutics*, 2007, **4**, 807-818.
15. Q. R. Huang, H. L. Yu and Q. M. Ru, *Journal of Food Science*, 2010, **75**, R50-R57.
16. A. R. Patel and K. P. Velikov, *Lwt-Food Science and Technology*, 2011, **44**, 1958-1964.
17. I. J. Joye and D. J. McClements, *Trends in Food Science & Technology*, 2013, **34**, 109-123.
18. K. Ahmed, Y. Li, D. J. McClements and H. Xiao, *Food Chemistry*, 2012, **132**, 799-807.
19. L. Zou, S. Peng, L. Gan, W. Liu, R. Liang, C. Liu, J. Niu, Y. Cao, Z. Liu and X. Chen, *Food Research International*, 2014, **64**, 492-499.
20. R. Zhang, Z. Zhang, H. Zhang, E. A. Decker and D. J. McClements, *Food Hydrocolloids*, DOI: <http://dx.doi.org/10.1016/j.foodhyd.2014.11.020>.
21. A. R. Patel, P. C. M. Heussen, E. Dorst, J. Hazekamp and K. P. Velikov, *Food Chemistry*, 2013, **141**, 1466-1471.
22. E. Troncoso, J. M. Aguilera and D. J. McClements, *Journal of Colloid and Interface Science*, 2012, **382**, 110-116.
23. K. Hu, X. X. Huang, Y. Q. Gao, X. L. Huang, H. Xiao and D. J. McClements, *Food Chemistry*, 2015, **182**, 275-281.
24. X. Chen, L. Q. Zou, J. Niu, W. Liu, S. F. Peng and C. M. Liu, *Molecules*, 2015, **20**, 14293-14311.
25. A. R. Patel, E. C. M. Bouwens and K. P. Velikov, *Journal of Agricultural and Food Chemistry*,

- 2010, **58**, 12497-12503.
26. G. Fricker, T. Kromp, A. Wendel, A. Blume, J. Zirkel, H. Rebmann, C. Setzer, R. O. Quinkert, F. Martin and C. Muller-Goymann, *Pharmaceutical Research*, 2010, **27**, 1469-1486.
 27. M. Minekus, M. Alming, P. Alvito, S. Ballance, T. Bohn, C. Bourlieu, F. Carriere, R. Boutrou, M. Corredig, D. Dupont, C. Dufour, L. Egger, M. Golding, S. Karakaya, B. Kirkhus, S. Le Feunteun, U. Lesmes, A. Macierzanka, A. Mackie, S. Marze, D. J. McClements, O. Menard, I. Recio, C. N. Santos, R. P. Singh, G. E. Vegarud, M. S. J. Wickham, W. Weitschies and A. Brodkorb, *Food & Function*, 2014, **5**, 1113-1124.
 28. Y. Li, M. Hu and D. J. McClements, *Food Chemistry*, 2011, **126**, 498-505.
 29. A. Bernkop-Schnurch and S. Dunnhaupt, *European Journal of Pharmaceutics and Biopharmaceutics*, 2012, **81**, 463-469.
 30. L. Sek, C. J. H. Porter, A. M. Kaukonen and W. N. Charman, *Journal of Pharmacy and Pharmacology*, 2002, **54**, 29-41.
 31. K. E. Barrett, *Gastrointestinal Physiology*, McGraw-Hill, New York, NY, Second Edition edn., 2014.
 32. A. G. P. Samaranyaka and E. C. Y. Li-Chan, *Journal of Functional Foods*, 2011, **3**, 229-254.
 33. R. J. Elias, S. S. Kellerby and E. A. Decker, *Critical Reviews in Food Science and Nutrition*, 2008, **48**, 430-441.
 34. C. J. H. Porter, N. L. Trevaskis and W. N. Charman, *Nature Reviews Drug Discovery*, 2007, **6**, 231-248.
 35. W. A. Birru, D. B. Warren, A. Ibrahim, H. D. Williams, H. Benameur, C. J. H. Porter, D. K. Chalmers and C. W. Pouton, *Molecular Pharmaceutics*, 2014, **11**, 2825-2834.
 36. F.-P. Chen, B.-S. Li and C.-H. Tang, *Food Research International*, 2015, **75**, 157-165.
 37. M. Li, J. Cui, M. O. Ngadi and Y. Ma, *Food Chemistry*, 2015, **180**, 48-54.
 38. K. Pan, Q. Zhong and S. J. Baek, *Journal of Agricultural and Food Chemistry*, 2013, **61**, 6036-6043.




Figure 1 (a). Particle size distributions of curcumin-loaded nanoparticle dispersions: lipid, phospholipid, and protein nanoparticles.




Figure 1 (b). Photographs of curcumin-loaded nanoparticle dispersions after preparation: lipid, phospholipid, and protein nanoparticles.




Figure 1 (c). Microstructure of curcumin-loaded nanoparticle dispersions measured using a confocal fluorescence microscope: lipid, phospholipid, and protein nanoparticles. The protein phase is stained green, whereas the lipid phase is stained red (see on-line color version).




Figure 2. Influence of simulated gastrointestinal conditions on the mean droplet diameter (d_{32}) of curcumin-loaded nanoparticle dispersions: lipid, phospholipid, and protein nanoparticles. Different lowercase letters mean significant differences ($p < 0.05$) of the droplet diameter of a delivery system between digestion phases; Different capital letters mean significant differences ($p < 0.05$) of the droplet diameter between delivery systems at same GIT stage.




Figure 3a. Influence of simulated gastrointestinal conditions on the particle size distributions of curcumin-loaded protein nanoparticles.




Figure 3b. Influence of simulated gastrointestinal conditions on the particle size distributions of curcumin-loaded phospholipid nanoparticles.




Figure 3c. Influence of simulated gastrointestinal conditions on the particle size distributions of curcumin-loaded lipid nanoparticles.




Figure 4. Influence of simulated gastrointestinal conditions on microstructure of curcumin-loaded nanoparticle dispersions: lipid, phospholipid, and protein nanoparticles. Nile red was added to highlight lipid-rich regions. The scale bars represent a length of 20 μm .




Figure 5. Influence of simulated gastrointestinal conditions on the particle charge of curcumin-loaded nanoparticle dispersions: lipid, phospholipid, and protein nanoparticles. Different lowercase letters mean significant differences ($p < 0.05$) of the particle charge of a delivery system between digestion phases; Different capital letters mean significant differences ($p < 0.05$) of the particle charge in different delivery systems within the same GIT phase.




Figure 6. Influence of nanoparticle composition on the NaOH titration profile of curcumin-loaded nanoparticle dispersions: lipid, phospholipid, and protein nanoparticles.




Figure 7. Influence of nanoparticle type on the concentration of curcumin solubilized within the mixed micelle phase after passage through a simulated GIT. All of the samples were significantly different ($p < 0.05$) from each other.

Table 1. The loading capacity, mean droplet diameters (Z-average, d_{32} , d_{43}), ζ -potential, and tristimulus color coordinates of protein, phospholipid and lipid nanoparticle suspensions was measured. Samples designated with different letters (a, b, c) were significantly different (Duncan, $p < 0.05$).


	Protein	Phospholipid	Lipid
Loading capacity (w/w)	11.7±0.8% ^c	3.1±0.3% ^b	0.4±0.0% ^a
ζ -potential (mV)	20.4±1.5 ^b	-5.2±3.3 ^a	-6.5±0.7 ^a
Z-average (nm)	153±5 ^b	89±30 ^a	192±12 ^c
PDI	0.23±0.04 ^a	0.32±0.10 ^a	0.200±0.04 ^a
d_{32} (nm)	99±2 ^a	99±1 ^a	168±17 ^b
d_{43} (nm)	124±3 ^a	124±1 ^a	241±12 ^b
<i>L</i>	52.2±4.2 ^b	34.4±0.5 ^a	91.8±0.0 ^c
<i>a</i>	-14.0±1.8 ^b	-20.2±0.1 ^a	-12.9±0.0 ^b
<i>b</i>	69.8±3.1 ^b	43.9±0.6 ^a	77.4±0.0 ^c

Table 2. Properties of samples collected after passage of protein, phospholipid, and lipid nanoparticle suspensions through a simulated GIT (mouth, stomach, small intestine). Samples designated with different letters (a, b, c) were significantly different (Duncan, $p < 0.05$).


	Protein	Phospholipid	Lipid
Transformation (%)	41±12 ^b	20.8±0.7 ^a	40 ±16 ^b
Bioaccessibility (%)	51.5±4.7 ^a	74.4±2.9 ^b	91.8±5.0 ^c
C_{Digesta} (µg/mL)	123.9±0.5 ^b	62.3±1.3 ^a	120.0±8.5 ^b
C_{Micelle} (µg/mL)	63±12 ^b	46.3±0.7 ^a	109±16 ^c
Mean diameter (nm)	203.1±16.3 ^c	110.3±22.9 ^a	144.1±3.7 ^b
PDI	0.60±0.04 ^c	0.40±0.09 ^b	0.23±0.01 ^a
ζ-potential (mV)	-12.6±4.4 ^a	-21.8±7.2 ^a	-59.8±1.6 ^b

Curcumin-loaded Colloidal delivery systems

**Protein
nanoparticles**



**Lipid
nanoparticles**



**Phospholipid
nanoparticles**

